OBJECTIVE: Because anti-inflammatory drugs may delay cognitive decline and influence brain metabolism in normal aging, the authors determined the effects of the cyclooxygenase-2 inhibitor, celecoxib, on cognitive performance and regional cerebral glucose metabolism in nondemented volunteers with mild age-related memory decline. DESIGN: Randomized, double-blind, placebo-controlled, parallel group trial with 18-months of exposure to study medication. SETTING: University research institute. PARTICIPANTS: Eighty-eight subjects, aged 40-81 years (mean: 58.7, SD: 8.9 years) with mild self-reported memory complaints butnormal memory performance scores were recruited from community physician referrals, media coverage, and advertising. Forty subjects completed the study. INTERVENTIONS:Daily celecoxib dose of 200 or 400 mg, or placebo. MAIN OUTCOME MEASURES: Standardized neuropsychological test battery and statistical parametric mapping (SPM) of FDG-PET scans performed during mental rest. RESULTS: Measures of cognition showed significant between-group differences in executive functioning (F [1, 30] = 5.06, p = 0.03) and language/semantic memory (F [1, 31] = 6.19, p = 0.02), favoring the celecoxib group compared with the placebo group. Concomitantly, FDG-PET scans demonstrated bilateral metabolic increases in prefrontal cortex in the celecoxib group in the vicinity of Brodmann's areas 9 and 10, but not in the placebo group. SPM analyses of the PET data pooled by treatment arm corresponded to a 6% increase in activity over pretreatment levels (p <0.01, after adjustment for multiple comparisons). CONCLUSIONS: These results suggest that daily celecoxib use may improve cognitive performance and increase regional brain metabolism in people with age-associated memory decline.
RCT Entities:
OBJECTIVE: Because anti-inflammatory drugs may delay cognitive decline and influence brain metabolism in normal aging, the authors determined the effects of the cyclooxygenase-2 inhibitor, celecoxib, on cognitive performance and regional cerebral glucose metabolism in nondemented volunteers with mild age-related memory decline. DESIGN: Randomized, double-blind, placebo-controlled, parallel group trial with 18-months of exposure to study medication. SETTING: University research institute. PARTICIPANTS: Eighty-eight subjects, aged 40-81 years (mean: 58.7, SD: 8.9 years) with mild self-reported memory complaints but normal memory performance scores were recruited from community physician referrals, media coverage, and advertising. Forty subjects completed the study. INTERVENTIONS: Daily celecoxib dose of 200 or 400 mg, or placebo. MAIN OUTCOME MEASURES: Standardized neuropsychological test battery and statistical parametric mapping (SPM) of FDG-PET scans performed during mental rest. RESULTS: Measures of cognition showed significant between-group differences in executive functioning (F [1, 30] = 5.06, p = 0.03) and language/semantic memory (F [1, 31] = 6.19, p = 0.02), favoring the celecoxib group compared with the placebo group. Concomitantly, FDG-PET scans demonstrated bilateral metabolic increases in prefrontal cortex in the celecoxib group in the vicinity of Brodmann's areas 9 and 10, but not in the placebo group. SPM analyses of the PET data pooled by treatment arm corresponded to a 6% increase in activity over pretreatment levels (p <0.01, after adjustment for multiple comparisons). CONCLUSIONS: These results suggest that daily celecoxib use may improve cognitive performance and increase regional brain metabolism in people with age-associated memory decline.
Authors: Daniel H S Silverman; Co T Truong; Shanna K Kim; Carol Y Chang; Wei Chen; Arthur P Kowell; Jeffrey L Cummings; Johannes Czernin; Gary W Small; Michael E Phelps Journal: Mol Genet Metab Date: 2003-11 Impact factor: 4.797
Authors: T Melnikova; A Savonenko; Q Wang; X Liang; T Hand; L Wu; W E Kaufmann; A Vehmas; K I Andreasson Journal: Neuroscience Date: 2006-06-06 Impact factor: 3.590
Authors: Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio Journal: N Engl J Med Date: 2006-12-21 Impact factor: 91.245
Authors: Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan Journal: Arch Neurol Date: 2008-05-12
Authors: Francesco Panza; Alessia D'Introno; Anna Maria Colacicco; Cristiano Capurso; Angelo Del Parigi; Richard J Caselli; Alberto Pilotto; Giovanni Argentieri; Pier Luigi Scapicchio; Emanuele Scafato; Antonio Capurso; Vincenzo Solfrizzi Journal: Am J Geriatr Psychiatry Date: 2005-08 Impact factor: 4.105
Authors: Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio Journal: Lancet Neurol Date: 2008-02 Impact factor: 44.182
Authors: Ross Andel; Michael Crowe; Nancy L Pedersen; Laura Fratiglioni; Boo Johansson; Margaret Gatz Journal: J Gerontol A Biol Sci Med Sci Date: 2008-01 Impact factor: 6.053
Authors: Amy H Moore; Matthew J Bigbee; Grace E Boynton; Colin M Wakeham; Hilary M Rosenheim; Christopher J Staral; James L Morrissey; Amanda K Hund Journal: Pharmaceuticals (Basel) Date: 2010-06-02